Roche bets $545M on Trophos’ once-failed orphan drug

Damian Garde

has signed a deal to trade up to €470 million ($ 545 million) for , a company at work on a mid-stage treatment for the rare and debilitating spinal muscular atrophy.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS